OUR PURPOSE Kuros Biosciences is on a mission to discover, develop and deliver innovative biologic technologies. OUR CREDENTIALS Kuros is a Swiss-headquartered biotech company, listed on the SIX Swiss Stock Exchange since 2016 (under symbol KURN). With additional operations in the Netherlands and the USA, we continue to grow our global team. To deliver the ideal bone graft, you need the highest quality and quantity of scientific evidence behind it. We believe that this is a key differentiator for Kuros, given the urgent need to advance bone healing. • Listing on the 𝗦𝗜𝗫 𝗦𝘄𝗶𝘀𝘀 𝗘𝘅𝗰𝗵𝗮𝗻𝗴𝗲 under the symbol KURN since 2016 • A commercial & research footprint that spans >𝟮𝟬 𝗺𝗮𝗿𝗸𝗲𝘁𝘀 • Dozens of 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗮𝗻𝗱 𝘀𝗰𝗶𝗲𝗻𝘁𝗶𝗳𝗶𝗰 𝗲𝘅𝗽𝗲𝗿𝘁 𝗮𝗱𝘃𝗶𝘀𝗲𝗿𝘀 • >𝟮𝟱 orthobiologics-related 𝗽𝗮𝘁𝗲𝗻𝘁𝘀 • >𝟰𝟬𝟬 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝗲𝘃𝗮𝗹𝘂𝗮𝘁𝗲𝗱 in Level I, randomized controlled clinical trials • >𝟮𝟬 well-controlled 𝗟𝗲𝘃𝗲𝗹 𝗜-𝗜𝗩 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹𝘀 𝗶𝗻𝗶𝘁𝗶𝗮𝘁𝗲𝗱, including 6 that are complete¹ • Published Level I evidence published in 𝑆𝑝𝑖𝑛𝑒 CONTACT KUROS TO FIND OUT MORE >>>>
全新 市場推廣與公關 活動 — 剛出現 54 個新訊號。
此公司進入各市場的次序 — 由最舊至最新
Kuros Biosciences Achieves Profitability Growth
𝗞𝘂𝗿𝗼𝘀 𝗮𝗻𝗻𝗼𝘂𝗻𝗰𝗲𝗱 𝘁𝗼𝗱𝗮𝘆 𝟰𝟱% 𝗛𝟭 𝟮𝟬𝟮𝟲 𝘆𝗲𝗮𝗿-𝗼𝘃𝗲𝗿-𝘆𝗲𝗮𝗿 𝘀𝗮𝗹𝗲𝘀 𝗴𝗿𝗼𝘄𝘁𝗵 𝗮𝗻𝗱 𝗶𝗻𝗰𝗿𝗲𝗮𝘀𝗲𝘀 𝗼𝘃𝗲𝗿𝗮𝗹𝗹 𝗽𝗿𝗼𝗳𝗶𝘁𝗮𝗯𝗶𝗹𝗶𝘁𝘆 A dozen milestones that mark our next phase of scale – see what’s driving the momentum: 1) Total Medical Device sales +45% to USD 92.4M 2) EBITDA increased 46% to USD 7.4M3) Adjusted EBITDA increased 61% to USD 12.5M (13.6% margin) 4) Net profit amounted to USD 4.4M5) Cash on track; funding U.S. and Netherlands expans ...
註冊以查看完整訊號動態
Kuros Biosciences 的國際擴張與競爭對手的比較
Kuros Biosciences你長條顯示所比較各公司之間的相對規模。
5 項指標| 公司 | 市場 | 新市場 | 動能 | 活動 | 擴張評分 |
|---|---|---|---|---|---|
 Kuros Biosciences你 | 2 | 0 | +1767% | 59 | 56 |
過去 90 日內開放了 7 個職位。 以 Information Technology 為主，集中於 荷蘭。
Bilthoven, Utrecht, Netherlands · 3日前
Supply Chain Analyst
San Francisco, CA · 2星期前
Regional Sales Manager - Northern California
Bilthoven, Utrecht, Netherlands · 3星期前
Warehouse and Customer Service Employee
整個技術架構共偵測到 28 項技術。
於 56 個市場進行 2 個活躍廣告活動。
已結束
已結束過去 90 日內有 3 則提及。
瑞士醫療科技公司Kuros Biosciences報告2026年上半年收入增長45%至9240萬瑞郎,淨利潤440萬瑞郎,由MagnetOs產品線推動。
Kuros Biosciences在喬治亞州開設生產設施,獲瑞銀買入評級。MagnetOs骨替代材料推動美國增長,第一季銷售增長51%至4340萬美元,目標2028年達3.3億美元。
Kuros Biosciences將在蘇黎世資本市場日展示MagnetOs™商業動能及可擴展的優質增長計劃。
解鎖已驗證電郵與直撥電話
免費 · 無需信用卡
關於 Kuros Biosciences 業務、市場及增長訊號的快速解答。
